Medline exits hospital and homecare bed business, sees costs of up to $220 million

Medline is pulling all of its Medline Brand beds off the market and getting out of the business, a move Medline estimates could cost up to $220 million.

The company began a voluntary field action on Oct. 14 covering the removal, discontinuation and market exit of all Medline Brand beds, including homecare, bariatric and long-term care beds, according to an 8-K filed Wednesday. The action also covers the beds' pendants, accessories, replacement parts and order packages that contain beds.

The affected products sit in the Front Line Care category of the company's Medline Brand segment. They generated about $60 million in net sales over the 12 months ended June 27, 2026.

The cost

Medline said it is too early to pin down the total cost, which includes product discontinuation, inventory impairment and disposal costs, and customer credits. Its current estimate is up to $220 million, to be incurred in 2026 and 2027.

The range reflects uncertainty about how many customers will participate, and actual customer credits may differ materially, the company said. Medline plans to exclude the costs from adjusted EBITDA.

Guidance intact

The company said it does not currently expect the action to have a material impact on its fiscal 2026 financial results, including the full-year guidance it issued on Aug. 5.

By the numbers

• Estimated costs: up to $220 million
• Trailing 12-month sales of affected beds: about $60 million
• Field action start: Oct. 14, 2026
• Cost timing: 2026 and 2027

Sources

1. Medline Inc., Form 8-K (Item 7.01), filed Oct. 21, 2026, accession 0001104659-26-117844

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.